Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × INDUSTRY × Abituzumab × Clear all

Phase

Phase 2 2 Phase 1 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

pembrolizumab 241 Carboplatin 134 Nivolumab 131 Gemcitabine 124 Paclitaxel 116 Cisplatin 104 Bevacizumab 95 Cyclophosphamide 90 Dexamethasone 76 Injections 75 Docetaxel 71 Pemetrexed 69 Fluorouracil 68 Capecitabine 64 Rituximab 61 atezolizumab 60 Cetuximab 60 Oxaliplatin 58 130-nm albumin-bound paclitaxel 58 Leucovorin 56 Ipilimumab 51 Lenalidomide 46 fludarabine 42 Azacitidine 40 Irinotecan 39 venetoclax 38 Albumin-Bound Paclitaxel 36 Prednisone 35 Fulvestrant 35 Trastuzumab 34

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01008475 2016-03-30

POSEIDON

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed

232 enrolled 20 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡